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1. Introduction 
Cilia and flagella are microtubule-based appendages extending from the basal body of most 
eukaryotic cells, and are classified as either motile or primary. Motile cilia or flagella can be 
found on many cells such as Chlamydomonas, sperm, and respiratory tract epithelial cells.  
This type of cilia is responsible for movement of the cell itself or generation of fluid flow. In 
contrast, primary cilia are non-motile organelles that are critically involved in visual, 
olfactory and auditory signal transduction and play key roles in the regulation of gene 
expression, development, and behavior. This chapter reviews the current understanding of 
the various mechanisms involved in cilia and flagellar assembly and maintenance. 
Consistent with the nearly ubiquitous cellular distribution, cilia have been implicated in 
numerous human diseases collectively known as ciliopathies. This chapter also discusses 
several major ciliopathies including primary ciliary dyskinesia, hydrocephalus, polycystic 
kidney disease, Bardet-Biedl syndrome, and cancer.  
2. Mechanics of ciliogenesis 
2.1 Basic biology of cilia 
Cilia and flagella are long, slender structures protruding from the body of ciliated cells and 
are composed of a microtubule-based core known as the axoneme.  The main structural 
element is an array of nine doublet microtubule pairs.  The a-subfiber of these pairs exists as 
a fully enclosed filament and is fused to the incomplete b-subfiber containing fewer tubulin 
subunits.  The individual pairs of subfibers are linked together by nexin proteins, forming 
an enclosed cylinder around a central pair of singlet subfibers; this layout is known as the 
“9+2” arrangement. The axoneme itself originates from the basal body, a modified form of 
the centriole consisting of nine triplet microtubules which anchors the cilia to the plasma 
membrane.  The area between the triplet microtubules of the basal body and doublet pairs 
of the axoneme is referred to as the transition zone.  Proteinaceous extensions from this area 
called transition fibers serve to mark the enclosure of the flagellar compartment and create a 
barrier from the cytoplasm.  The outer and inner dyneins, located on the a-subfiber of the 
axoneme, are motor proteins that produce the bending and sliding of the microtubules by 
exerting force on the b-subfiber via ATP hydrolysis.  Defects in the inner and outer motor 
complexes can yield paralyzed or uncoordinated sliding of the axoneme, resulting in 
inefficient movement.  The outer doublet ring and the central pair of microtubules are 
connected by structures known as radial spokes [1]. 
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Cilia can be distinguished into two types:  primary (nonmotile) and motile cilia.  While they 
have the same basic structure, the biological functions of these two types can be very 
different.  Primary cilia typically do not contain the central pair of microtubules (having a 
“9+0” structure), and also lack other accessory proteins important for generating the ciliary 
waveform stroke.  This form of cilia is considered a sensory antenna for the cell due to a 
highly specialized membrane protein profile and ability to extend in the luminal space of 
various tissues.  Historically, motile cilia/flagella are known to be important for locomotion 
in single-celled organisms.  In humans, however, motile cilia are important for various 
physiological processes, ranging from mucous clearing in the trachea to aiding in 
establishing proper left-right symmetry in developing organisms [2].  Because of their 
structural similarities, the terms cilia and flagella will be used interchangeably.   
2.2 Intraflagellar transport at a glance 
Intraflagellar transport (IFT) is a term used to describe the bi-directional movement of non-
membrane protein particles that move along the microtubule doublet core (or axoneme), 
between the space of the ciliary membrane and the axoneme.  IFT was originally discovered 
by Kozminksi and colleagues in 1993, using digital interference contrast (DIC) microscopy 
to visualize the continuous movement of “bulges” beneath the membrane of a 
Chlamydomonas reinhardtii mutant with paralyzed-cilia [3].  Anterograde movement, towards 
the ciliary tip or plus end of microtubules, is powered by heterotrimeric kinesin-2, and 
retrograde movement is driven by cytoplasmic dynein1b [4-14].  A multi-meric protein 
complex known as the IFT particle attaches to the motor complex and is itself comprised of 
two large protein sub-complexes [5].  The axoneme is undergoing constant turnover at its 
tip, meaning tubulin and other accessory proteins must be constantly replenished at the 
distal tip [15].  The well-conserved IFT motors and particles are tasked with assembling and 
maintaining the whole cilia structure by serving as adaptors for the transport of axonemal 
precursors and the recycling of turnover products [1]. A secondary, though equally 
important, function of IFT is to ferry in ciliary membrane proteins through a secondary 
adapter complex known as the BBSome [16, 17].     
2.2.1 IFT Motors 
2.2.1.1 Anterograde motor 
First isolated in sea-urchin, the anterograde IFT motor is a heterotrimeric kinesin-2, 
comprised of three individual subunits [18].  Homologs are found in a variety of ciliated 
organisms, including Tetrahymena, Caenorhabditis elegans, and humans.  In Chlamydomonas, 
FLA10 and FLA8 comprise the motor portion of the complex and together they interact with 
FLA3, a kinesin-associated protein [19].  First evidence for the role of the kinesin-2 in 
anterograde movement came from the characterization of a temperature sensitive mutant in 
FLA10.  While incubated at the permissive temperature (22°C), the biflagellated green algae 
possess two, full-length flagella. However, following a shift to the non-permissive 
temperature (32°C), FLA10 subunit denatures and levels of IFT proteins significantly reduce 
within the first hour [6].  Cessation of IFT results in the dismantling of the axoneme and the 
entire ciliary structure is retracted back into the cell body because of the normal turnover [5].  
In addition, an isolated null mutant for the FLA10 subunit produces no flagella [20].  Taken 
together, these studies demonstrate the importance of kinesin-2 to ciliogenesis. 
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These observations, however, are not entirely consistent among all ciliated organisms.  
Mutations in the kinesin-2 motor subunits of different species do not result in a cilia-less cell 
phenotype because of a secondary, homodimeric kinesin known as OSM-3 in C. elegans and 
KIF17 in Homo sapiens[13].  Studies investigating the function of OSM-3 conclude that the 
canonical kinesin-2 motor and OSM-3 work in a concerted effort to build sensory cilia in C. 
elegans [13].  Single mutants in KLP-11 (FLA8) and KAP-1 (FLA3) in C. elegans appear to 
form intact sensory cilia due to the redundancy of OSM-3 function in ciliogenesis (Signor et 
al, 1999).  However, perturbations of OSM-3 results in loss of the ciliary distal segment 
comprised of singlet microtubule extensions beyond the doublet axoneme core.  In these 
mutants, the heterotrimeric anterograde motor still allows formation of the middle segment.   
It could be possible the transferring of the IFT particle from the canonical kinesin-II to OSM-
3 may insure proper, sequential construction of the cilia.  However, it has been well 
documented that OSM-3 speed actually increases in disrupted kinesin-II mutants [21], 
suggesting that kinesin-II may in fact be negatively regulating OSM-3.  If so, kinesin-II 
would ultimately be involved in determining the re-supply rate of axonemal precursors to 
the flagella compartment.  Defects in retrograde IFT clearly demonstrate the negative impact 
that excess precursors and turnover products have on proper ciliary function.  Therefore, 
accumulation of axonemal components, due to a faster influx of proteins by OSM-3, could 
also unbalance the natural turnover vs. assembly in favor of creating longer cilia, which is a 
phenotype that has been observed in kinesin-II mutants.  Recently, a null mutant for a 
relatively new kinesin, KLP-6 in C. elegans males, demonstrated a slower procession of OSM-
3/KAP-1-associated IFT particle within the ciliary compartment [22].  Although it was 
observed moving independently of the canonical IFT particle/motor complex, KLP-6 
function may have a positive influence on ciliary length.  This conclusion is supported by a 
reduction of klp-11/klp-6 double mutant cilia compared to the single klp-11 mutant; klp-11 
mutant has comparatively longer cilia than wild-type.  
2.2.1.2 Retrograde motor 
IFT-dynein, cytoplasmic dynein 2 (previously known as dynein 1b), powers the retrograde 
movement of IFT [12].  To date, four proteins are confirmed members of the dynein 2 
complex: heavy chain DHC1b, light chain LC8, light intermediate chain D1bLIC, and an 
intermediate chain FAP133 [7-9, 14, 23-25].  C. elegans null mutants defective in dynein 
components undergo normal anterograde movement but accumulate large amounts of IFT 
proteins and turnover products within the ciliary compartment [26].  Retrograde-defective 
cilia are severely truncated and contain protein aggregates that appear as noticeable large, 
electron-dense clots.   These results suggest IFT dynein is responsible for the retrograde 
movement of the IFT; this result has been seen in Chlamyomonas, where defects in IFT dynein 
lead to protein accumulations in the flagella compartment [27].  Anterograde movement 
remains active in these mutants; however, the characteristic bulbous cilia are present as a 
result of axonemal turnover outpacing the dysfunctional retrograde IFT.  It has become 
fairly evident that IFT particles do not passively diffuse out of the flagella compartment and 
turnover products must be actively removed by dynein 2 in order to allow unhindered 
trafficking of the IFT trains.   
The current model for retrograde activation is fragmented at best.  IFT-dynein is carried into 
the compartment in an inactivated form as part of the IFT cargo.  Once it reaches the tip, a 
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poorly understood remodeling occurs, initiating the dynein-powered return of the IFT train 
back to the cell body [27, 28].  During retrograde movement, the kinesin is inactivated, but it 
is unknown whether kinesin-2 is removed by the IFT particle as part of the turnover cargo 
or simply diffused out.  IFT-dynein has been historically shown to associate with complex A 
in Chlamydomonas, primarily due to IFT-A temperature sensitive mutants exhibiting similar 
phenotypes as retrograde mutants [29, 30].  During remodeling at the distal tip, IFT-A likely 
facilitates the activation of dynein-2 in order to initiate retrograde movement, although a 
detailed mechanistic overview is lacking [28].   
The newest addition to the retrograde movement model suggests OSM-3 and kinesin-II may 
directly transport IFT dynein, independently of the IFT particle in C. elegans [11].  The 
conclusion is derived from IFT-dynein undergoing normal IFT transportation speeds 
despite the uncoupling of IFT complex A/kinesin-2, and complex B/OSM-3.  Another new 
concept suggests IFT172 may in fact mediate the interaction between inactivated dynein and 
the IFT particle during anterograde movement [28].  A new study in C. elegans has revealed 
the presence of a new retrograde dynein motor, specific to outer labial quadrant neurons, 
which are able to form full functional cilia in canonical IFT dynein mutants [11].  
2.2.1.3 Regulation of the motors 
IFT motor regulation continues to be of high interest in the cilia field due to the motors’ 
important functions.  Defects in FLA3, the kinesin associated protein, lead to mislocalized 
kinesin-II and subsequently produce a bald or flagella-less phenotype in Chlamydomonas 
[31].  Isolation of DYF-11 null mutant, a homolog of human microtubule-interacting protein 
(MIP)-T3 and IFT54 in C. elegans, reveals that this protein may serve as an anchoring protein 
for the priming/loading of the entire IFT motor/particle complex onto the transition zone of 
cilia [32]. KIF17, OSM-3 homolog of C. elegans, in human primary cilia was discovered to be 
under the regulation of a RAN gradient between the cell body and flagellar compartment.  
This mechanism operates in similar fashion to the RAN gradient active in regulating the 
trafficking of proteins across the nuclear pore complex [33].  A ciliary localization signal 
(CLS) at the tail end of KIF17 was shown to contribute to the interaction with another 
accessory protein known as importin-ǃ2, a nuclear import protein; this interaction was 
inhibited by RAN-GTP.  Similar CLS signals may exist for additional proteins in other 
model organisms due to the conserved nature of IFT.  Recent study into the regulation of 
IFT-dynein flagellar entry has suggested that Chlamydomonas IFT172, a peripheral protein of 
IFT-B subcomplex, may be directly involved in the transport of IFT-dynein into the flagellar 
compartment [28].   
2.3 IFT particle 
By comparing the flagellar proteome of a fla10ts mutant after incubation at the non-
permissive temperature to a wild-type proteome, Cole and colleagues biochemically 
observed the depletion of certain proteins from the flagellar compartment [5].  After further 
analysis, members of the IFT particle were discovered. Results from this study 
demonstrated that the IFT particle was actually comprised of two sub-complexes, IFT-A and 
IFT-B, which to date consist of 6 and 12 polypeptides, respectively [19].  A recent study shed 
new light on the organization of the IFT-B subcomplex, demonstrating it can be separated 
further into two tetrameric subdomains: IFT25/27/74/81/72 and IFT52/46/88/70 [34-36].  
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IFT52 serves as the interface between the IFT74/81 and IFT52/46/88/70 [36]; IFT74/81 
functions as the intermediate complex between IFT25/27 and IFT52/46/88/70.  Currently 
IFT-A complex is understood to be composed of IFT144/121/140/121/139/43 [30], however 
its structural organization remains unclear.   
A majority of the IFT members are enriched in WD40 and tetracopeptide repeats (TPR), 
multi-protein binding domains that possibly form a circularized beta-propeller structure 
and alpha helical solenoid, respectively, to behave as scaffolding elements [19].  WAA is 
another binding motif present in these proteins, although it is poorly understood.  Most of 
the IFT proteins contribute to the overall integrity of their respective complexes, evident by 
the subsequent instability and depletion of complex-mates following disruption of certain 
IFT proteins. Depending on which complex is disrupted, flagella morphology is typically 
affected in one of two ways: structurally sound but severely truncated cilia (IFT-B mutants) 
or short bulbous flagella (IFT-A) [1, 13, 27]. The resulting phenotype reveals the different 
nature of the two complexes; short flagella convey IFT-B’s importance in anterograde 
movement and protein buildup in the flagella compartment suggest IFT-A is involved in 
retrograde IFT.  Nonetheless, the many parts of IFT machinery must work in a concerted 
effort to strike an efficient balance between retrograde and anterograde transportation 
dynamics.   
Defects in other IFT-B proteins typically lead to a bald phenotype, making any biochemical 
analysis a challenge to determine individual function.  A null mutant of ift88, the first IFT 
protein to be implicated in disease [37], displays a bald phenotype in Chlamydomonas.  The 
absence of IFT54/MIP-T3 causes the entire IFT motor/particle complex, with the exception 
of OSM-3, to mislocalize at the ciliary base in C. elegans [32].  In IFT46 mutants, IFT-B 
complex still assembles the complex B core proteins but stability is severely affected, evident 
by the presence of structural sound yet short flagella in Chlamydomonas [38].  A suppressor 
IFT46 mutant sufficiently stabilizes the IFT complex to produced full length flagella.  
However, upon closer analysis, the axoneme lack outer dynein arms [38].  Thus, IFT46 
serves as an adaptor protein for the specific transport of ODA16, a component of the outer 
dynein arms [39].  It is unclear whether IFT46 functions as a structural protein, since it 
appears not to be an essential contributor to complex B structural integrity (Richey and Qin, 
unpublished). It could possess a secondary function as a molecular indicator or chaperone 
for the IFT-B complex assembly, since the IFT-B can still assemble on a sucrose density 
gradient (Richey and Qin, unpublished). In addition to the known IFT core proteins, there 
are a few peripheral proteins associated with complex B: IFT57, IFT20, IFT172, and IFT80 
[34].  IFT20 is a particularly interesting protein, because it is the only IFT protein that can 
localize in the Golgi apparatus, the central hub for the sorting and packaging of 
macromolecules for secretion.  The current model suggests IFT20 is involved in directing 
vesicles transporting ciliary-specific proteins near the basal body, and participating in the 
trafficking of membrane proteins into the flagellar compartment [40].  IFT57 can target to the 
transition fibers of the axoneme, and serves as an anchoring protein for IFT20 to IFT-B in 
zebrafish [41].  IFT172 is also an interesting protein, since it readily dissociates from the IFT 
particle and has been shown to be important for retrograde movement.  Using temperature 
sensitive mutant fla11ts (IFT172), Pederson et al. 2006 concluded that IFT172 directly 
interacts with CrEB1, a protein exclusively located at the flagella tip, and accumulates IFT-B 
but not IFT-A nor IFT dynein proteins in the flagella [42, 43].   Recently, evidence of IFT172 
involvement in the flagellar entry of IFT-dynein was detected in Chlamydomonas. Upon 
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incubation at the non-permissive temperature, IFT-dynein is depleted from the flagella 
compartment of the temperature sensitive IFT172 mutant while the rest of IFT particle 
remains at wild-type levels [28].     
The function of individual IFT-A sub-complex proteins are even more enigmatic.  Much like 
IFT-B proteins, disruption or depletion of a single IFT-A protein leads to the instability of 
the complex and subsequent depletion from the cell body [28].  Mouse IFT122 was shown to 
regulate members of the sonic hedgehog pathway in a number of ways by uniquely 
affecting the localization of certain proteins differently than IFT-A and IFT dynein mutants 
[44].  In Drosophila, an IFT140 mutant does not have detectable levels of ciliary TRPV ion 
channels; while the mRNA levels were unchanged, IFT140 may instead be important for the 
post-translational stability of the ion channels [45].  The more predominant understanding 
of the IFT-A function comes from its importance to retrograde movement.  At the 
permissive temperature, electron-dense bulges are present within the cilia of temperature-
sensitive Chlamydomonas mutants in IFT139 (fla17) and IFT144 (fla15).  Following a shift to 
the non-permissive temperature leads to the complete breakdown of retrograde IFT and 
retraction of the axoneme, resulting in lolli-pop shaped bulbs filled with IFT-B proteins [29, 
30].   This phenotype is also observed in IFT dynein mutants, thought to arise from the 
possible hindrance of retrograde IFT activation, and ultimately leading to the buildup of 
turnover products and IFT particles within the flagellar compartment [43].  In C. elegans, 
IFT-A directly interacts with kinesin-II while IFT-B is transported by OSM-3.  IFT-A and IFT-
B are linked together by the BBSome, a secondary adaptor complex important for ciliary 
membrane biogenesis [21, 46].     
2.4 BBSome role in membrane biogenesis 
Originally discovered during genetic disease screens, the BBSome protein complex functions 
as an adaptor complex for the IFT particle and facilitates the transport of ciliary membrane 
proteins.  Interaction assays using BBS4 led to the discovery of the seven conserved proteins, 
BBS1/2/4/5/7/8/9, that comprise the BBSome complex [47]. In the same study, BBS5 was 
found to interact with phosphoinositides, phospholipids important for recruitment of 
trafficking proteins to the plasma membrane, implicating a role for the BBSome in vesicle 
trafficking.  In addition, the BBS1 was shown to interact with Rabin8, a guanine nucleotide 
exchange factor (GEF) for Rab8, two proteins important for ciliary protein trafficking [16].  
BBS1 direct association with Rabin8 stimulates the protein’s GEF-activity to promote Rab8 
activation.  Rab8 and Rabin8 contribution to ciliogenesis will be discussed below.  Arl6 
(BBS3), although not important for BBSome assembly, is important for the recruitment of 
BBSome to primary cilia and purified liposomes [48].  In Chlamydomonas, perturbation of 
BBSome proteins does not lead to any morphological defects; however, cells are unable to 
undergo phototaxis, suggesting a role in signal transduction.  The ciliary membrane in BBS1, 
BBS4, and BBS7 mutants accumulate several proteins which are thought to hinder Ca2+ 
signaling pathways involved in the phototaxic response [17].  In C. elegans, the BBSome 
serves as a linking bridge between IFT-A/kinesin-II and IFT-B/OSM-3; disruption of the 
complex results in the uncoupling of the IFT machinery and leads to cilia morphology 
defects in some cases [21, 46].  Protein models predict the BBSome functions as a vesicle 
coat, much like clathrin and COPI/II coat, directing post trans-Golgi network (TGN) vesicles 
to  the ciliary compartment and accompanying them as a mediator between the IFT 
machinery [48].  The BBSome also sporadically “falls off” the IFT train, possibly in the event 
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of cargo unloading [17].  However, only a few ciliary membrane proteins have been 
confirmed to be BBSome-dependent for proper localization, most notably Somatostatin 
receptor 3 (SSTR30) and some G-coupled receptors.  Thus, it is unclear whether the BBSome-
dependent ciliary transport is a general mechanism or a protein-specific system [17].    
2.5 Role of GTPases in ciliogenesis 
Research in small GTPases involved in ciliogenesis is a growing branch of the field and the 
results have been quite interesting.   ADP-ribosylating factor–like (ARL) 13, BBS3 and the 
BBSome are involved in the targeting and entry of flagellar membrane proteins into the 
compartment [16].  ARL-13 and ARL-3 are small G-proteins antagonistically operating to 
maintain the stability of IFT particles during middle segment transport in C. elegans (IFT A 
and B) [49, 50].  ARL-13 may also have roles involved in maintaining axonemal integrity 
since null mutant animals have a variety of gross cilia abnormalities [49-51].  It has been 
suggested that ARL13 may in fact regulate the coupling of IFT-A and IFT-B, while ARL3 
regulates IFT-B interaction with OSM-3; together they regulate the integrity of the IFT 
machinery in C. elegans [50].  Rab8 is recruited to the transition zone by Rabin8 (Rab8GEF), 
following stimulation from BBS1, a core member of the BBSome; this ultimately results in 
the fusion of post-Golgi vesicles shuttling ciliary membrane proteins near the basal body 
[52, 53].  Dominant negative and constitutive active constructs demonstrate the impact that 
the nucleotide state of Rab8 has on its entry  into the ciliary compartment and its role in 
ciliogenesis [47].  Arf4 and Rab11 form a complex with Arf GTPase activating protein 
ASAP1 and FIP3 to package and transport rhodopsin from the trans-golgi-network to 
photoreceptor cilia [54].   This interaction between rhodopsin and Arf4 is dependent on a 
VxPx motif, a ciliary localization signal also found in other ciliary membrane proteins [16].  
Recently, the VxPx motif  has been shown to be essential for the trafficking of polycistin-1 
protein, and to be involved in the recruitment of Rab8, thereby promoting fusion of ciliary 
membrane protein-containing vesicles [55].  Another small GTPase, Rab23, was found to be 
responsible for the turnover of sonic hedgehog signaling protein, Smoothened, from the 
ciliary compartment [56].  As mentioned in IFT motor regulation section, a RAN-GTP 
ciliary/cytoplasmic gradient regulates the entry of kinesin motor KIF17 in the primary cilia 
of cultured cells [33].  
Two mysterious members of the IFT-B complex, IFT27/RABL4 and IFT22/RABL5, are the 
only small GTPases known to directly interact with the IFT particle.  IFT25 is a 
phosphoprotein of unknown function , though it is known to interact with the small 
GTPase-like IFT27 [57].  Recent work on IFT27 confirmed its GTP binding and GTPase 
activity along with solving the crystal structure of the sub-complex IFT25/27.  However, the 
exact function of IFT25/27 remains unknown [58].  IFT22 has been the more controversial of 
the two, since in recent studies with C. elegans and Trypanosome IFT22 homologs produced 
conflicting results.  In C. elegans, a putative constitutive active form (GTP-locked) of the 
IFTA-2 (IFT22 homolog) can enter the ciliary compartment while dominant negative (GDP-
locked) diffusely localizes throughout the neuronal cell body and is notably excluded from 
the ciliary compartment [59]. IFTA-2 null mutants exhibited extended lifespans, reminiscent 
of insulin IGF-1-like signaling pathway defects, and a failure to enter dauer formation, a 
type of survival mode.  The null IFTA-2 (IFT22) mutant had intact sensory cilia, effectively 
suggesting IFTA-2 is not essential to ciliogenesis.  However, RNAi knockdown experiments 
of  Trypanosome  RABL5 lead to the buildup of IFT particles in the flagella compartment and 
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subsequent shortening of the flagella [60].  This phenotype is similar to mutants with 
defective retrograde IFT, suggesting RABL5 is important for ciliogenesis.  
2.6 Gating the ciliary compartment 
As mentioned above, the transition fibers mark the entrance of the flagella compartment by 
tethering the plasma membrane to the base of the flagella.  The ciliary proteome contains 
various proteins not found   at such concentrated levels in cytoplasm, implying an inherent 
selectivity to the transition zone barrier [61].  Although the complete regulatory pathway 
remains poorly understood, various studies have begun to demonstrate the complexity of 
the flagella gating mechanism.  Recent biochemical characterization of cep290 mutant in 
Chlamydomonas revealed that the protein CEP290 functions as an intricate member of the 
transition zone barrier proteins [62].  CEP290 is part of the MKS/MKSR/NPHP proteins 
(Meckel-Gruber syndrome/related and nephronophthisis), shown to localize at the base of 
the flagella.  Together these proteins form the transition zone and function as the ciliary 
selective barrier, evident by the accumulation of non-ciliary proteins in the cilia of various 
TZ mutants [63, 64].  Although IFT anterograde movement was normal and retrograde 
slightly slower, the cep290 flagella accumulated IFT-B proteins and BBS4, yet had a 
reduction of IFT-A, some membrane proteins and axonemal precursors.  This phenotype 
suggests CEP290 plays a role in the mechanical selectivity of the transition zone; it could be 
possible that IFT-B binding/priming at the transition zone requires CEP290, which could 
explain the mostly unhindered movement of IFT and the buildup of IFT-B and not IFT-A.   
Additional selectivity mechanisms have become more apparent, such as the requirement of 
ciliary transport signal (CTS) for access to the flagella compartment [16].  The VxPx motif, a 
CTS, is important for the targeting and entry of ciliary membrane proteins polycistin-1 and 
rhodopsin.  In contrast, a recent study discovered a mechanism for molecular retention, 
whereby passive diffusion into the ciliary membrane is inhibited by a transferable retention 
signal [65].  Podoclayxin was shown to contain a four- amino acid PDZ binding motif that 
facilitated its interaction with NA+/H+ exchanger 3 regulatory factor NHERF1, a protein 
attached to the apical actin cytoskeleton [66].  The conserved four- amino acid sequence in 
the PDZ binding motif was shown to be sufficient to prevent passive diffusion into the 
cilary membrane domain [65].  Although the ciliary entry is passive, the ciliary membrane 
protein retention appears to require the protein to be firmly attached to the axoneme.  Thus, 
a ciliary retention signal is likely to be necessary for membrane protein accumulation in the 
ciliary compartment.  Additionally, much like the gating system for the nuclear pore 
complex, a RAN-GTP has been found to exist between the cilia and cytosol that is important 
for import of KIF17, via its Ran-GTP dependent association with importin-ǃ2 [33].   
2.7 Microtubule post translational modifications 
The microtubule component of the axoneme undergoes various post-translational 
modifications (PTMs) that play a vital role in promoting the mechanical movement of the 
organelle.  The dramatic impact of microtubule PTMs has been well characterized, but 
recent studies have begun to deepen our understanding of how PTMs affect ciliary assembly 
and maintenance.  For an extensive review on the impact of PTMs on ciliogenesis and cell 
motility, please see a recent review by Wloga and Gaertig [67, 68]. 
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2.7.1 Acetylation of tubulin 
N-Acetylation is the only PTM that occurs within the microtubule core, at the highly 
conserved K40 residue on ǂ-tubulin [69-71].  Mammalian microtubules undergo acetylation 
of lysine residues on multiple sites located on both ǂ- and ǃ- tubulin [72].   Recently MEC-
17, a previously uncharacterized protein now known as ǂTAT1 (ǂ-tubulin 
acetyltransferase), may be the sole enzyme responsible for the acetylation of K40 in 
mammalian cilia [73].  Knockdown of ǂTAT1 does not produce any severe morphological 
defects nor does it affect microtubule polymerization.  However, as a BBSome-associated 
protein, it was suspected to be involved in cilia assembly.  The depletion of ǂTAT1 leads to a 
delayed assembly of primary cilia; taken together with recent information, K40 acetylation 
may be involved in the dynamics of axonemal assembly and disassembly [74].  Recent 
studies demonstrate that acetylation of ǂ-tubulin may target these subunits for degradation, 
since they are preferentially selected to be ubiquitinated over ǃ-tubulin during disassembly 
[75].  A newly discovered BBSome subunit, BBIP10, functions as a positive regulator of 
microtubule stability, as a reduction of cytoplasmic microtubules and increase in free 
tubulin is seen in BBIP10-depleted cells.  In addition, overexpression of BBIP10, microtubule 
acetylation was dramatically increased.  The function of BBIP10 on microtubule stability 
appears to be either dependent or independent of the BBSome [76]   
2.7.2 Glutamylation and glycylation 
Glutamylation has been observed on microtubules in general, while glycylation has been 
found to be restricted to the ciliary microtubules of flagellated cell types [77].  These side 
chains are synthesized in distinct steps of initiation and elongation, typically carried out by 
two types of enzymes known as tyroslytubulin ligase-like proteins (TTLLs) [78, 79].  Recent 
studies have begun to investigate the function of these types of PTMs for ciliogenesis, most 
notably by the impact of polyglutamylation on inner dynein dynamics [80, 81].   
3. Ciliopathies 
Ciliated cells can be found in various tissues throughout the human body.  These include 
the eye, the trachea, the kidney, the reproductive tract, the intestines, the heart, and many 
others.  In each of these tissues, the cilia perform a significant role in allowing proper 
function of the tissues.  Since ciliated cells are in most important organ tissues, 
malfunctioning cilia contribute substantially to human disease.  Diseases caused or related 
to faulty cilia are called ciliopathies.  The list of ciliopathies is just as diverse as the variety of 
tissues in which cilia are found.  These diseases support the fact that cilia, once thought to be 
unimportant cellular appendages, are essential for sustaining health in the human body.  
There are too many ciliopathies to mention, and the list continues to grow.  Some major 
ciliopathies include Primary Ciliary Dyskinesia (PCD), Hydrocephalus, Polycystic Kidney 
Disease (PKD), Bardet-Biedl Syndrome (BBS), and even cancer [82]. 
3.1 Primary Ciliary Dyskinesia (PCD) 
The relationship between Primary Ciliary Dyskinesia (PCD) and ciliary defects was first 
discovered in the 1970’s [83], making PCD the first human disorder found to be linked to 
cilia function [84].  PCD is a multi-symptomatic ciliopathy that is present in all major ethnic 
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groups and occurs 1 in every 20,000 live births, although this is likely an underestimation 
due to a failure to properly diagnose the disorder [85, 86].  PCD was first called “immotile 
cilia syndrome,” but was renamed because it was later found that the cilia were not always 
immotile, but often had abnormal motility [87].   
PCD is characterized by many symptoms that are expressed to various degrees [84].  It 
affects mainly the respiratory system beginning at birth or within the first month of life.  
Early signs typically involve a persistent cough and chronic nasal congestion.  Other 
symptoms often include other respiratory problems such as sinusitis and bronchiectasis [87].  
The respiratory symptoms of PCD are caused by the lack of uniform ciliary movement to 
transport particles, or mucous in or out of the organs or the cells themselves. There are 
about 200 motile cilia in the respiratory tract of a healthy individual.  Beating coordinately, 
these cilia function to remove mucous and debris from the airway in a process called 
mucocilliary clearance [88].  When the cilia malfunction, there is buildup of mucous and 
debris in the tract, which leads to respiratory difficulties. 
However, this disease is not only associated with the respiratory system.  It also has an 
impact in development, fertility, and aural health.  Fifty percent of patients with PCD have 
total situs inversus, with organs developing on the opposite side of the body.  This is 
thought to be due to the importance of cilia in producing correct direction of nodal flow 
during embryo development.  This was seen in a 2002 study which showed that when 
direction of nodal flow was artificially reversed to right instead of left, mice developed 
organs that were a mirror image to normal orientation [89].  There are three known genes 
involved in left-right axis (LRA) determination, including lrd (left-right dynein), hfh-4 
(hepatocyte nuclear factor/forkhead homologue 4), and kif3B (kinesin member 3B) [90-92].  
PCD also affects fertility.  Males with PCD are typically infertile, and females have a higher 
rate of ectopic pregnancies.  Significant hearing impairment is seen in about fifty percent of 
children with PCD [93].  This is likely due to the condition known as chronic secretory otitis, 
which is found almost universally in PCD patients [94].  This is a condition that causes 
collection of fluid in the middle ear and can cause serious hearing loss and pain. Studies 
have been done to show that people with chronic secretory otitis have a slower ciliary beat 
frequency, resulting in failure to move fluid out of the ear canal, leading to infection [95].   
PCD is a genetically heterogeneous disease typically caused by autosomal recessive 
mutations in ciliary protein genes.  The most common mutations occur in DNAH5 (dynein 
heavy chain) and DNAI1 (intermediate chain dynein) genes.  Studies show that the disease 
is caused by abnormalities in the axonemal structure of the cilia.  In most patients, the outer 
dynein arms are missing, of which fifty percent of these patients have mutations in DNAH5 
and DNAI1 [96-98].  However, it is thought that lacking the inner dynein arms, central pair 
of microtubules, or radial spokes can also lead to PCD.  Seventy to eighty percent of patients 
have outer or inner dynein arm defects, while only five to ten percent are missing radial 
spokes.  PCD can also be caused by a disorientation of cilia and transposed microtubules 
[85].  Transposed microtubules occur when a cilium lacks the central microtubule pair and a 
peripheral doublet with dynein arms transposes to the center of the axoneme.  This 
microtubule defect, coined “central microtubule agenesis,” causes a circular rotation of the 
cilia rather than the normal back and forth motion [99].  In addition to genetic causation, 
PCD can also be a result of acquired defects caused by epithelial damage by chronic 
infection or irritant exposure [100]. 
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Beat frequency, beat patterns, and protein localization are all parameters measured in 
diagnosis of the disease.  Nasal brush biopsies are most commonly used to collect a patient’s 
cells, but bronchoscopic brush biopsies can also be used [101].  Typically, a diagnosis is 
made by examining fixed cells under a transmission electron microscope to identify ciliary 
structural defects in addition to measuring ciliary beat frequency in live cells by video 
microscopy.  However, in the case of central microtubule agenesis, it is important to also 
look at ciliary beat pattern, since the cilia typically maintain a normal beat frequency, with 
aberrant movement.  These patients also tend to have normally functioning nodal cilia, 
which allow normal situs, accounting for the fact that not all PCD patients have situs 
inversus [99].  This may pose a problem for diagnosis if doctors are using organ orientation 
as a diagnostic factor.  Protein localization is a relatively new and uncommon means of 
diagnosis.  In respiratory cells, certain ciliary proteins have been shown to mislocalize in the 
case of PCD.  These include DNAH5 and DNAI1, which under normal circumstances, 
colocalize throughout the axoneme.  In patients with PCD caused by a mutation in the 
DNAI1 gene, the protein fails to localize to the distal tip, leading to abnormal motility.  In 
patients with a mutation in DNAH5, the protein is entirely absent from the axoneme, 
causing complete paralysis.  This is useful for diagnosis since immunofluorescence can 
show if this mislocalization is present [102].  Genetic testing can also be done, but is not very 
reliable since the disease is very genetically heterogeneous, with the discovery of at least ten 
related genes from various loci on multiple chromosomes [103].  False positive diagnoses 
can occur during or after a respiratory infection or inflammation, since these conditions 
show impaired ciliary function.  Therefore diagnosis is only accurate at least four to six 
weeks post-infection [101]. 
Screening for the disease is also very important to help rule PCD out for patients with 
similar symptoms. Among the screening techniques, measuring levels of nasal nitric oxide 
(nNO) is relatively new but fairly promising.  Very low levels of nNO are exhaled from 
patients with PCD.  Therefore, if the patient has high or normal levels, they likely do not 
have PCD.  Levels are not diagnostic of PCD, however, since low levels can also be found in 
accordance with other diseases such as cystic fibrosis, chronic sinusitis, and others.  One 
downfall of this screening technique is that it is ineffective for children under five years old, 
since younger children will not be able to blow into the apparatus [104].  Saccharin testing is 
also used for PCD screening.  This is a measurement of the time it takes for a patient to be 
able to taste saccharin, which is related to the function of the cilia in the taste bud cells.  
However, this is not a very useful test since it is unreliable in children under twelve.  
Radioaerosol mucociliary clearance testing, which measures how well mucous is removed 
from the respiratory tract, is useful in infants for screening, but again is not diagnostic of 
PCD [101]. 
Current treatment for PCD is mainly focused on treating and preventing the symptoms of 
the disease.  Studies are being done to test the efficacy of antibiotics, airway clearance, and 
anti-inflammatory treatments [101].  Nebulized DNase has also shown promise in a 1999 
case study with a PCD patient.  The patient’s symptoms were not relieved from treatment 
with antibiotic and bronchodilator treatments alone.  However, when DNase was used in 
addition to these treatments, there was a significant improvement in symptoms overnight.  
This showed the therapeutic potential of DNase, but more studies need to be done to further 
test the efficacy [105].  Gene therapy is also being considered.  A 2010 pilot study showed 
that a lentiviral vector can incorporate ciliary protein into the axoneme to restore ciliary 
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function [96].  Further studies need to be done to make these treatments more mainstream.  
In addition to treatments, preventative measures such as avoiding respiratory irritations and 
exercising, can be very helpful.  If treatments and preventative measures are unsuccessful, it 
is often necessary to undergo surgery.   
PCD research has taught us a lot about cilia.  It has shown the importance of cilia in 
development, in respiratory function, in aural health, and in fertility.  It has also taught us a 
lot about the structure of cilia and the function of various ciliary proteins.  In fact, a 2010 
study revealed 208 potential ciliary genes based on PCD research [106].  PCD will continue 
to give us new insights on ciliary function and will continue to be an important area of 
ciliopathy research. 
3.2 Hydrocephalus 
Hydrocephalus is a disease in which cerebral spinal fluid (CSF) accumulates in the brain.  
CSF is mostly produced by the choroid plexuses of the lateral, third, and fourth ventricles 
[107].  To maintain equilibrium it is important for the excess fluid to drain into the 
subarachnoid space where it is resorbed into the venous system [108].  When this process 
malfunctions, the fluid builds up, causing swelling in the brain that leads to many 
complications.  The disease dates back to the time of Hippocrates when he described a 
“liquefaction of the brain” that showed symptoms such as headache, vomiting, and visual 
impairment [109].  Other symptoms can include high intracranial pressure, in addition to 
impairments in gait, cognition, alertness, and continence [110].  Although this disease can 
have various causes, it has been shown that there is a higher prevalence of hydrocephalus in 
patients that are known to have ciliary defects, and the disease can also be linked to genes 
known to impact cilia function or structure [111]. Hydrocephalus is often seen in 
conjunction with other ciliopathies such as PKD as seen in the Tg737 mouse [112] and more 
rarely in PCD [113].   
Although hydrocephalus has a rich history in research, the disease as a ciliopathy is a 
relatively new area of study, and much is yet to be learned about its link with cilia.  In 
animal models, 43 mutations from 9 different genes are known to be related to 
hydrocephalus.  In contrast, there is only one gene that has been identified in humans [114].  
X-linked hydrocephalus is caused by a mutation in the neural cell adhesion molecule L1 
(L1CAM) gene [115].  This form of the disease was first discovered in 1949 [116] and occurs 
about 1 in every 30,000 male births [117].  No research has been done up to this point to 
determine if there is a link between L1CAM and cilia.   
Many mouse models, however, have allowed identification of multiple ciliary genes that, 
when mutated, can lead to hydrocephalus.  Accumulation of CSF can be caused by 
malfunctions in CSF production, CSF flow, or CSF absorption.  Tg737 mice are missing 
intraflagellar transport protein IFT88/Polaris.  This protein is important for ion transport 
and the mutation shows an overproduction of CSF, leading to the development of 
hydrocephalus [107].  This suggests the importance of cilia in signaling and regulation of 
CSF levels.  Mice with this mutation also have abnormal beating of the motile cilia of the 
ependymal cells, disrupting the CSF flow.  However, this is not causal in this case since 
development of the disease occurs before the motile cilia form [107].  In contrast, CSF flow 
disruption seems to be the cause of hydrocephalus in Mdnah5 (axonemal dynein heavy 
chain) and Hydin mutants.  These mutants cause structural defects in the axoneme of the 
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cilia, leading to impaired motility [111, 118-120].  In these two mutants, the cilia are unable 
to create sufficient flow to remove CSF from the ventricles.  Other hydrocephalus mutants 
are thought to be linked to important development pathways that may disrupt the CSF 
equilibrium. Inactivation of Pten and ǃ-catenin leads to hydrocephalus [121].  These proteins 
are key players in Wnt signaling pathway and important for proper midbrain development, 
in which the function of primary cilia could be involved [122].  Polycystin-1, a ciliary 
membrane protein, is also shown to be important in development and regulating fluid in the 
brain [112].  Ptch1 and parkin-qk1 mutations also lead to hydrocephalus [123] most likely 
due to a disruption in the Hedgehog pathway, which also involves the primary cilia [124].  
All these findings show the importance of cilia in signaling, development, and movement of 
fluid, and their roles in maintaining a healthy CSF balance in the brain. 
An early method of diagnosis required ventricular puncture to test for dilation and 
occlusive lesions.  This procedure was risky, so it was eventually replaced by computed 
tomography (CT) and magnetic resonance imaging (MRI) [109].  Prenatal diagnosis can be 
done for x-linked recessive hydrocephalus by doing serial ultrasound scans to test for 
abnormal growth of the baby’s head [125].  Since there is only one known human 
hydrocephalus gene, and it is for the rare x-linked type, genetic testing is not yet useful for 
diagnosis.   
The oldest treatment known for hydrocephalus was to tightly bandage the baby’s deformed 
swollen head to decrease the size and swelling.  This method was abandoned since it 
increased the intracranial pressure.  In the 18th and 19th centuries, special diets were 
recommended and dehydration was induced with laxatives, diuretics, potassium iodide, etc.  
In 1957 acetazolamide was first used in practice and is still used to reduce production of 
CSF.  Other treatments were abandoned such as isosorbide and irradiation of the choroid 
plexus [109].  Vasoconstrictors such as dihydroergotamine have shown promise in allowing 
better arterial pulsation and reducing ventricular dilation [126].  Various surgical treatments 
have been used including external CSF drainage, serial lumbar puncturing, and 
implantation of an internal shunt, which is a catheter that allows drainage of CSF out of the 
ventricles. These surgical procedures brought about complications such as infections, 
improper placement of shunts, and hydraulic mismanagement due to body positioning.  
These complications necessitated further research and improvements.  One of the most 
pivotal improvements is the development and modification of shunts with adjustable, 
autoregulating, antisiphon, and gravitational valves.  There are currently at least 127 designs 
of valves and more than 20 shunting procedures that have been suggested, with 
ventriculoperitoneal shunts being the most commonly utilized.  Valved shunts are now 
standard treatment for hydrocephalus, being the choice treatment for about 80% of cases 
[109, 127].  In elderly patients shunt implantation is very risky.  Repeated lumbar 
puncturing in patients with communicating hydrocephalus can potentially prevent the need 
for shunt surgery in these patients [110].  The newest addition to shunt technology is 
antibiotic-impregnated shunts that help prevent post-surgical infections [128]. 
The relationship between cilia and hydrocephalus and the genes that are involved are 
poorly understood in humans.  Advancements in this knowledge may eventually lead to 
better, less invasive forms of treatment and a better understanding of how cilia function in 
the brain. 
www.intechopen.com
 
Current Frontiers and Perspectives in Cell Biology 436 
3.3 Polycystic Kidney Disease (PKD) 
There are two types of PKD, autosomal dominant polycystic kidney disease (ADPKD) and 
autosomal recessive polycystic kidney disease (ARPKD).  ADPKD is the most common of all 
the potentially lethal autosomal dominant diseases, with an incidence of 1 in 1000 [129].  
Symptoms typically do not present themselves until between the ages of 35-50 years.  These 
symptoms include acute abdominal and lower back pain, hypertension, palpable kidneys, 
recurrent urinary tract infections, shortness of breath, early satiety, hydrocephalus, kidney 
stones and cysts in the kidney, liver, thyroid, subarachnoid space, and seminal vesicles [130].  
ADPKD most often ends in end stage renal disease (ESRD) between 55 and 75 years old [82]. 
ARPKD, on the other hand presents itself immediately. Although delayed presentation is 
possible, ARPKD can often be seen in utero, and leads to ESRD in the neonatal stage and 
infants often die due to respiratory complications.  Also unlike ADPKD, there is usually no 
cyst formation in other organs in the case of ARPKD [130].  It is also much more rare, with an 
incidence of 1 in 20000, and has a very high infant mortality rate [131]. 
Although other factors may be involved, strong correlations have been made between PKD 
and cilia function.  Primary cilia are now known to act as mechanosensors that regulate Ca2+ 
influx.  Fluid flow in the kidney causes the primary cilia to bend, which allows the Ca2+ 
channels to open, allowing increased intracellular Ca2+.  This process is disrupted in some 
forms of PKD.  However, primary cilia have also been implicated in pathways such as 
Hedgehog, Wnt, cAMP, and Planar Cell Polarity.  Disruptions of these pathways can lead to 
abnormal polarity, differentiation, and proliferation, which can lead to cyst formation [130].  
Therefore the role of primary cilia in cystogenesis is not only important, but is very 
multidimensional. 
In human, ADPKD is caused by a mutation in PKD1 (85 % of the time) or PKD2 (15% of the 
time). There are more than 500 mutations known in PKD1 and 120 in PKD2 [132, 133].  
These genes code for proteins polycystin-1 and polycystin-2, which both localize to renal 
cilia [134]. These proteins prove to be important in renal tube development and cell 
differentiation in the kidney.  They are involved in the calcium signal transduction cascade 
that regulates proliferation and differentiation [135, 136].  ARPKD is caused by a mutation 
in PKHD1, which encodes fibrocystin, a receptor-like protein associated with the membrane 
and colocalizes with polycystin-2 in primary cilia [82, 137].  It also plays a role in collecting 
duct and biliary cell differentiation [138].  Studies in other species have made other 
connections between cilia and PKD.  In addition to hydrocephalus, Tg737 mice have cysts in 
kidney and pancreas, hepatic fibrosis, and polydactyly.  Mice with this mutation have 
elevated polycystin-2 levels and have cilia that are much shorter than normal [135, 139].  
These factors result in cyst formation.  A mutation in Kif3A (a subunit of kinesin-II in kidney 
epithelium) causes increased canonical Wnt activity.  Deletion of this gene leads to absence 
of cilia, and after the cilia are lost, cystogenesis occurs [140].  Seahorse is another mutation 
that shows a disruption in Wnt signaling in zebrafish and may function downstream from 
cilia [141].  Out of the 11 genes identified in zebrafish that relate to PKD, 6 were found to be 
ciliary genes [142].  These mutants and more, show the importance of cilia and pathways in 
regulating renal cells. 
Although CT and MRI techniques can be used, diagnosis by ultrasound and positive family 
history are the choice methods to test for PKD [143].  ARPKD can even be detected in utero 
by ultrasound which reveals large kidneys that take up most of the fetal abdominal cavity 
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and the lack of urine in the bladder [130].  Nuclear magnetic resonance (NMR) spectroscopy 
also allows discrimination between PKD and other kidney diseases with an accuracy of over 
80%, by creating a fingerprint of urinary protein biomarkers with key PKD features [143].  
Since most PKD patients have mutations in known PKD genes, genetic testing may be 
plausible.  However, since there are hundreds of possible mutations, the only commonly 
used genetics testing is direct sequencing to screen for the disease [144]. 
There is currently no effective treatment that is widely used for PKD.  Transplantation and 
dialysis are often the only options.  Apart from that, pain control, antibiotics for urinary 
tract infections, increase in fluid intake, and refraining from smoking and caffeine, are ways 
of lessening the symptoms [130].  However, many potential drugs for treating cystogenesis 
are under investigation.  Many drugs have shown to slow cyst growth in animal models.  
Rapamycin helps regulate cell proliferation by inhibiting the mTOR pathway, which is often 
overexpressed in PKD patients.  This drug increases apoptosis and shedding of cystic cells, 
which decreases kidney size and restored kidney function [145].  Roscovitine, currently used 
in cancer treatment because it  inhibits cell cycle, show positive effects in PKD models [146].  
Lisinopril, an inhibitor of angiotensin converting enzyme (ACE) also alters proliferative and 
apoptotic pathways, reducing cyst development [147].  Patients with PKD show high levels 
of circulating vasopressin.  Tolvaptin is a vasopressin-2 receptor antagonist and shows 
reduction in kidney and cyst volumes [148].  Ocreatide, an analogue of the hormone 
somatostatin, inhibits cAMP production.  In doing so, it inhibits secretion and reduces liver 
cysts and kidney volume.  However, it does not seem to improve renal function [149, 150].  
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibition using EKI-785 also 
showed promise in PKD animal studies [151].  Anti-inflammatory drug, colchicine, is a 
microtubule inhibitor that has been shown to delay formation of cysts and is a candidate for 
prolonged clinical use [152]. 
PKD mutants are giving us a better understanding of the importance of cilia in many 
regulatory pathways and sensory functions.  The disease further emphasizes how complex 
these seemingly simple cellular organelles are, and how necessary they are in maintaining 
systemic health and prevention of cystic growth. 
3.4 Bardet-Biedl Syndrome (BBS) 
Many syndromes are related to cilia, Bardet-Biedl syndrome being the most well-known.  
Bardet-Biedl Syndrome (BBS) is a multi-symptomatic disorder with symptoms including 
obesity, retinitis pigmentosa, genital hypoplasia, polydactyly, and mental retardation [153].  
Typically at age 8, night blindness occurs which can eventually lead to complete blindness 
between ages 15 and 20.   Kidney cysts are also common, making end-stage renal failure the 
most common cause of premature death in BBS patients [154].  Mid-facial deformities are 
often seen in humans with BBS and also in mice mutants for BBS4 and BBS6 [131].  Although 
this is a very multi-symptomatic disorder, obesity is what it is most known for.  Ninety-
eight percent of BBS patients become obese with a body mass index greater than 30% [155].  
Diabetes occurs secondary to obesity, and patients often show lower locomotor activity than 
normal [156, 157]. 
Phototransduction proteins and others necessary for vision are produced in the inner 
segment of photoreceptor cells. To maintain the outer segments, the phototransduction 
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proteins have to be transported to the outer segments of the photoreceptors through the 
connecting cilia, the only bridge between outer and inner segments. BBS proteins form a 
BBSome and are believed to be responsible for recruiting membrane vesicles to the cilia [16, 
47].  BBS proteins are also involved in important pathways such as Wnt and Hedgehog 
pathways which are very important for proper development and function [153].  Hedgehog 
and Wnt signaling are anti-adipogenic, preventing obesity [158-160].  It is now believed that 
obesity in BBS patients is linked to the impairment of ciliated cells in the hypothalamus to 
sense satiety, inducing hyperphagia [161].  BBS proteins may be important in transport of 
leptin in and out of the cells, causing loss of leptin signaling ability when cilia are lost.  
Moreover, melanin concentrating hormone receptor-1 (Mchr1) is involved in regulation of 
feeding behavior, and fails to localize to cilia in BBS mutants [161, 162].  These are just a few 
of the possible factors that may be involved in causing obesity in BBS patients. 
BBS is an autosomal recessive disease showing pleiotropy, with multiple traits being 
affected.  Development of the disorder often requires more than three mutations in at least 2 
BBS genes [163].  Apart from the causative mutations, other BBS mutations often serve as 
disease modifiers.  So far there are 12 known BBS genes, BBS1-12, which code for proteins 
important in trafficking cargo to the basal body and along the cilia.  Other ciliary proteins 
have also been linked to BBS [154]. Among these are Kif3A and Tg737 mutants, which show 
hyperphagic activity and obesity, in addition to elevated plasma levels of glucose, insulin, 
and leptin [164]. 
Diagnosis of BBS typically requires the presence of at least four primary symptoms or three 
primary in addition to two secondary symptoms.  Primary symptoms include cone-rod 
dystrophy, polydactyly, obesity, learning disability, genital defects, and renal anomalies.  
Secondary symptoms include speech impairment, brachydactyly (short digits), syndachtyly 
(fused digits), developmental delay, polyuria (excessive urination), ploydypsia (excessive 
thirst), ataxia (lack of muscle coordination), diabetes, heart and liver problems, olfactory 
deficits, and defects in pain and temperature sensation [154]. 
Since BBS is syndromic and affects multiple systems, treatment can be multi-faceted.  Gene 
therapy has shown promise in treating vision impairments.  Mice, in which Bbs4 has been 
deleted, show an inability of rhodopsin to localize to rod cilia and cone opsins to localize to 
cone cilia. This failure to localize leads to photoreceptor apoptosis and the deterioration of 
electroretinogram (ERG) a- and b-waves, causing serious vision impairment.  Recently, 
adeno-associated viral (AAV) vectors have shown to be successful in incorporating Bbs4 
into these mutants and restoring the localization of rhodopsin.  In doing so, photoreceptor 
death was prevented, function of the retina was restored, and mice showed recovery of 
visual behavioral responses [165].  Surgical techniques are used for other symptoms of BBS.  
For instance renal transplantation is used in the case of cystic kidneys.  Obesity is important 
to treat, since it has been shown to cause a fifty percent increase in mortality rates most 
likely caused by complications from secondary diseases. These include diabetes, 
cardiovascular diseases, cerebrovascular diseases, digestive disorders, gall bladder cancer, 
breast cancer, endometrium cancer, prostate cancer, etc [166, 167].  Bariatric surgeries such 
as gastric bypass and gastric band operations greatly improve weight loss in patients with 
obesity.  These operations also show a dramatic improvement in reducing the risk of 
secondary diseases that are known to be associated with obesity.  Because of the reduction 
in the incidence of these diseases, the mortality rate decreases substantially [168].  In 
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addition to surgical procedures, drug treatments have also been under review for the 
treatment of obesity.  There are only two drugs currently accepted by the U.S. Food and 
Drug Administration for long term obesity treatment.  This is due to the high prevalence of 
severe side effects correlated with the use of weight loss drugs.  These side effects include 
heart attack, gastrointestinal distress, liver damage, anxiety, memory problems, suicide, and 
are often habit-forming.  Because of these serious issues, it is important to be skeptical in 
determining which drugs are safe to be used to treat obesity [169].  These are only a few of 
the current treatments being used for BBS-related symptoms, and many others are yet to be 
discovered. 
Again, BBS adds further support to the idea that cilia are important in many areas 
throughout the body, and they are very important in maintaining the overall health of the 
individual.           
3.5 Cancer 
Relating cancer to cilia is one of the newest areas of ciliary research in the field today.  The 
cilia assembly-disassembly cycle is closely linked with the cell cycle.  Cilia assemble upon 
exit of mitosis to the stationary phase, and resorb when the cell exits the S-phase and enters 
mitosis [170].  When the ciliogenesis is disrupted, it may have adverse effects on cell cycle 
and lead to cancer.  This may be due to centrosomal amplification and genetic instability 
[171].  Proteins necessary for ciliogenesis colocalize to the centrosome, also supporting the 
link between cilia and cell cycle [172].  Cilia have also been found to play roles in important 
pathways such as Sonic Hedgehog, signal transduction pathways, and ligand-induced 
signaling.  These pathways have recently been shown to relate to cancer.  New insights are 
being made to connect ciliary dysfunction to carcinogenesis [172]. 
Primary cilia appear to have dual opposing functions in development of different types of 
cancer, so that some refer to them as being an On/Off switch, regulating tumorigenesis [173, 
174].  One of the most important pathways related to ciliogenesis and cancer is the Hedgehog 
(Hh) pathway.  Hh is normally suppressed by Ptch1 which prevents the trafficking of Smo in 
primary cilia.  When Smo fails to localize to cilia, it prevents Hh signaling.  Under cancerous 
conditions, however, Smo is able to localize to the cilia and Hh signaling is overexpressed 
leading to oncogenesis [175].  SmoM2 leads to brain tumors only if primary cilia are present.  
However, Gli2∆N induces brain tumors only in the absence of cilia, since absence of cilia 
causes a disruption in Gli3, a repressor of Gli2∆N [174, 176].  It appears that primary cilia are 
required both for the suppression and expression of oncogenisis.  Primary cilia suppress 
oncogenic mutations that act downstream of cilia, but allow expression of oncogenic 
mutations upstream of cilia [173, 174, 177].  Therefore, cilia can play opposite roles depending 
on the causal mutation of the cancer development [173, 174].   
Disruptions in Hh, Wnt, and PDGF pathways all have been linked to tumor formation.  
Cilia-associated genes such as Gli1, RPGRIP1, and DNAH9 are often mutated in breast 
cancer [177].  Nek8 is also localized to cilia and upregulated in breast cancer [178, 179]. 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in 
the United States [180].  In this case, excessive Hh signaling is caused by a mutation in a 
Kras gene[181], which codes for a protein known to be important in ciliogenesis.  Therefore 
affected cells lack primary cilia, and are unable to regulate proliferation [182]. 
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German pathologist, Rudolf Virchow, first defined cancer in the mid-1800s when he realized 
that Leukemia was caused by a rapid duplication of healthy cells that had mutated and in 
response, multiplied. Before the advent of modern-day technology, cancer was not 
diagnosed or treated until the tumors became visible and palpable, in which case they were 
surgically removed.  Since then, however, an emphasis has been placed on early detection so 
that doctors can treat the cancer before it turns into large fatal tumors.  Most doctors 
recommend certain regular screening for some types of cancer. Among these are 
mammograms for breast cancer, colonoscopies for colon cancer, Pap smears for cervical 
cancer, and prostate exams for prostate cancer.  Other diagnostic tests include blood tests, 
ultrasounds, computed tomography (CT), X-ray, magnetic resonance imaging (MRI), and 
fine-needle biopsies.  These techniques are used to detect early signs of cancer, allowing an 
earlier treatment and an attempt to prevent fatality [183].     
Cancer treatment is one of the most prioritized areas of research today.  Many treatments 
are currently being used and even more are being tested. These treatments include 
chemotherapy, radiation therapy, surgery, and gene therapy.  Perhaps the implications in 
the relationship with cilia and cell cycle will help lead to the development of new 
treatments.  
Primary ciliary dyskinesia, hydrocephalus, polycystic kidney disease, Bardet-Biedl 
syndrome, and cancer are only a few of the known ciliopathies, and more are still being 
discovered.  These diseases are not only important to study for diagnostic and treatment 
purposes, but also give us a clearer understanding about cilia and their role in most critical 
bodily functions.  Further ciliopathy studies will continue to shed new light on these 
important cellular structures.   
The research in the Qin lab is supported by the NSF grant MCB-0923835.  
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